Tetraphase Pharmaceuticals, Inc.

Bayer Healthcare LLC

Other

Bayer Pharmaceuticals Corporation

Cornerstone Therapeutics, Inc.

The Feinstein Institutes for Medical Research

Roger B Clark

Xiao-Yi Xiao

Louis Plamondon

Minsheng He

Diana Katharine Hunt

Cuixiang Sun

Soongyu Choi

Xin Ma

Martin F Hentemann

Magnus Ronn

Joachim Rudolph

Rico C Lavoie

Louis-David Cantin

Magnus Rönn

Robert Zahler

Daniel Elbaum

Jingye Zhou

Wu-Yan Zhang

Christiana Akuche

Zhonghua Zhang

Sidney Xi Liang

Philip L Wickens

Chi-Li Chen

Dyuti Majumdar

Libing Chen

Yonghong Deng

Harold L Hull

Roger Astbury Smith

Ann-Marie Campbell

Andrew G Myers

Stephen J O'Connor

Tatiana Shelekhin

Derek B Lowe

Joyce A Sutcliffe

Ziyang Zhang

Philip Coish

Xiben Li

Trudy Grossman

Takehiro Fukuzaki

Jeffrey Stebbins

Wenying Wang

Sushmita D Lahiri

Udara Anulal Premachandra Ilandari Dewage

Jonathan F Lawrence

Senkara Rao Allu

Wesley Francis Austin

Yoshitaka Ichikawa

Derek Lowe

Magnus Roenn

Joyce Sutcliffe

Robert B Zahler

Provided are macrolide compounds for the treatment of infectious diseases. The macrolides disclosed herein include 14-membered ketolides and 14-15-membered azaketolides, and may comprise modified sugars which are desosamine analogues. The disclosed macrolides may have a bicyclic structure. Also provided are pharmaceutical compositions and methods of treating infectious diseases, and in particular, disease which results from Gram negative bacteria using the disclosed macrolides. This disclosure additionally provides methods of preparing the macrolides by a strategy that enables late-stage modification of the 6'-position of the sugar moiety, thereby allowing facile access to previously difficult-to-make macrolide compounds.

Macrolides with modified desosamine sugars and uses thereof

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Tetracycline compounds

Tetracyline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use. 

Disclosed are novel piperazine derivatives that act as agonists of the &#x3b1;7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Piperazines, pharmaceutical compositions and methods of use thereof

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

Polycyclic tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use. 

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

C7-fluoro substituted tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): 

8-AZA tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use. 

This invention is directed to indole acetic acid derivatives and their use in pharmaceutical compositions for the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease. The invention is also directed to intermediates useful in preparation of indole acetic derivatives and to methods of preparation.

Indole acetic acid derivatives and their use as pharmaceutical agents

Growing community of inventors

Lexington, MA, United States of America

Roger B Clark